Browse > Article
http://dx.doi.org/10.14374/HFS.2020.28.4.429

Review of Research for Herbal Medicine on Systemic Sclerosis  

Roh, Jong Seong (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University)
Kim, Sang Chan (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University)
Byun, Sung Hui (Department of Herbal Prescription, College of Korean Medicine, Daegu Haany University)
Yoon, Michung (Division of Medical Engineering and Health Management, Mok-Won University)
Shin, Soon Shik (Department of Formula Sciences, College of Korean Medicine, Dong-Eui University)
Sohn, Dong Hyun (Department of Microbiology and Immunology, Pusan National University School of Medicine)
Publication Information
Herbal Formula Science / v.28, no.4, 2020 , pp. 429-441 More about this Journal
Abstract
Objectives : Systemic sclerosis(SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs and vasculopathy. The purpose of this study was to investigate the trend in the research on SSc using herbal medicine. Methods : We searched for papers which had both systemic sclerosis and herbal medicine from Pubmed, KCI and NDSL. After searching papers, we classified according to the study design and analyzed selected studies. Results : 18 studies were searched. The types and numbers of study were as follows: 11 were in vitro or in vivo studies using herbal medicine or active components, and 7 were clinical research including case reports. 1. Herbal medicines include the therapeutic effects of "tonifying qi(補氣)" or "active blood(活血)" improved systemic sclerosis in vivo and in vitro studies. 2. Active components isolated from Herbal Medicine such as Astragalus membranaceus(黃芪), Zhizi(梔子), Salvia miltiorrhiza(丹蔘) have anti-fibrotic effects. 3. Clinical trials showed that herbal medicine can improve the symptom of systemic sclerosis including skin fibrosis, Raynaud's phenomenon, pain and gastric dysmotility. Conclusions : This study showed that herbal medicine can be effective for treating SSc. However, further studies are needed to develop novel medicine for SSc.
Keywords
Systemic sclerosis; Herbal medicine; Fibrosis;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Park JH, Yoon J, Lee KY, Park B. Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFbeta/Smad and ERK-MAPK signaling pathways. Biochimie. 2015;113:26-34.   DOI
2 Yang K, Luo Y, Lu S, Hu R, Du Y, Liao P, et al. Salvianolic Acid B and Ginsenoside Re Synergistically Protect Against Ox-LDL-Induced Endothelial Apoptosis Through the Antioxidative and Antiinflammatory Mechanisms. Front Pharmacol. 2018;9:662.   DOI
3 Yu F, Lu Z, Chen B, Wu X, Dong P, Zheng J. Salvianolic acid B-induced microRNA-152 inhibits liver fibrosis by attenuating DNMT1-mediated Patched1 methylation. J Cell Mol Med. 2015;19(11):2617-32.   DOI
4 Liu M, Xu H, Zhang L, Zhang C, Yang L, Ma E, et al. Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem Biophys Res Commun. 2018;495(1):325-31.   DOI
5 Cao L, Huang B, Fu X, Yang J, Lin Y, Lin F. Effects of tanshinone IIA on the regulation of renal proximal tubular fibrosis. Mol Med Rep. 2017;15(6):4247-52.   DOI
6 Balanescu P, Balanescu E, Balanescu A. IL-17 and Th17 cells in systemic sclerosis: a comprehensive review. Rom J Intern Med. 2017;55(4):198-204.   DOI
7 Lee BW, Kim SC, Byun SH, Kim HK, Jee SY. Study on Duties and Abilities of a Human's Mentality[five kinds of mental activities]-Oriental Medicine's Outlook on Mentality-. J Korean Med Classics. 2004;17(1): 198-217.
8 Luan L, Liang Z. Tanshinone IIA protects murine chondrogenic ATDC5 cells from lipopolysaccharide-induced inflammatory injury by down-regulating microRNA-203a. Biomed Pharmacother. 2018;103:628-36.   DOI
9 Brown M, O'Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310-21.
10 Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-99.   DOI
11 Su M, Tian F, Ouyang B, Wu X, Guo F, Chen H, et al. Bufei Qingyu Granules Inhibit the Development of Systemic Sclerosis via Notch-1/Jagged-2 Signaling Pathway. Evid Based Complement Alternat Med. 2019;2019:6709278.
12 Wang Q, Shi G, Zhang Y, Lu F, Xie D, Wen C, et al. Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Sci Rep. 2019;9(1):355.   DOI
13 Bian H, Fan YS, Lou LH, Mao BY, Shi JY. [Effect of Wenyang Huazhuo Tongluo recipe contained serum on proliferation and cell cycle of systemic sclerosis skin fibroblasts]. Zhong Yao Cai. 2009;32(6):936-9.
14 Bian H, Lv Q, Huang XZ, Hu JL, Yang L, Mao BY. [Effects of Wenyang Huazhuo Tongluo Recipe Containing Serum on Transforming Growth Factor beta1/ Smad Signaling Pathway of Skin Fibroblasts in Systemic Sclerosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(9): 1054-9.
15 Han L, Bian H, Ouyang J, Bi Y, Yang L, Ye S. Wenyang Huazhuo Tongluo formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis. BMC Complement Altern Med. 2016;16:69.   DOI
16 Wang Q, Zang W, Han L, Yang L, Ye S, Ouyang J, et al. Wenyang Huazhuo Tongluo formula inhibits fibrosis via suppressing Wnt/beta-catenin signaling pathway in a Bleomycin-induced systemic sclerosis mouse model. Chin Med. 2018;13:17.   DOI
17 Wu T, Chu H, Tu W, Song M, Chen D, Yuan J, et al. Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis. BMC Complement Altern Med. 2014;14:224.   DOI
18 Qi Q, Mao Y, Yi J, Li D, Zhu K, Cha X. Anti-fibrotic effects of Astragaloside IV in systemic sclerosis. Cell Physiol Biochem. 2014;34(6):2105-16.   DOI
19 Qi Q, Mao Y, Tian Y, Zhu K, Cha X, Wu M, et al. Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model. Am J Transl Res. 2017;9(3):1025-36.
20 Liu Q, Lu J, Lin J, Tang Y, Pu W, Shi X, et al. Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis. Biomed Pharmacother. 2019;110:546-53.   DOI
21 Jiang Y, Hu F, Li Q, Shen C, Yang J, Li M. Tanshinone IIA ameliorates the bleomycin-induced endothelial-to- mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis. Int Immunopharmacol. 2019;77:105968.   DOI
22 Bian H, Yuan M, Gao Z-m, Bi XD, Han L, Hu JL, et al. [Effect of Wenyang Huazhuo Tongluo Recipe on Peripheral Blood Thl7/Treg Cell Balance in Systemic Sclerosis Patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35(8):975-80.
23 Zhou J, Yang D, Zhou SH, Wang JP, Liu YS, Wang SL. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial. Chin J Integr Med. 2018;24(3):185-92.   DOI
24 Jang S, Yoon S, Ryu J, Lim J, Han S, Kim H, et al. A Case Report of Korean Traditional Medical Therapy on Gastric Dysmotility Involved in Patient with Systemic Sclerosis Sine Scleroderma. Korean J Orient Int Med. 2004;25(2):344-51.
25 Park SH, Do TY, Lee SH, Lee JY. A Case Report of Clinical Effects of Complex Korean Medicine Treatment in Patients with Scleroderma Caused by Juvenile Idiopathic Arthritis. J Pediatr Korean Med. 2019;33(4):26-36.
26 Liu XS, Gao Y, Zheng LW, Hua H. New alternative therapy for orofacial localized scleroderma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(3):e15-9.
27 Kim MK, Jeong JG, Kim KM, Kim HJ, Kim JH, Kim YI, et al. The Effect of Korean Medical Treatment on Systemic Sclerosis : A Case Report. The Acupuncture. 2016;33(3):207-18.   DOI
28 Jang Y, Kim J, Kim H, Lee G, Lim S. A Case of Raynaud's Syndrome Modified by Secondary Systemic Sclerosis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(4): 108-16.   DOI
29 Kim H. Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. The Korean Journal of Medicine. 2014;87(4):395-400.   DOI
30 Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castaneda AR, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int. 2019;2019:4569826.   DOI
31 Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-93.   DOI
32 Asano Y. Systemic sclerosis. J Dermatol. 2018;45(2):128-38.   DOI
33 Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-39.   DOI
34 Oliver GF, Winkelmann RK. The current treatment of scleroderma. Drugs. 1989;37(1):87-96.   DOI
35 Yang Y, Yang S, Chen M, Zhang X, Zou Y, Zhang X. Compound Astragalus and Salvia miltiorrhiza Extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts. J Ethnopharmacol. 2008;118(2):264-70.   DOI
36 Barsotti S, Orlandi M, Codullo V, Di Battista M, Lepri G, Della Rossa A, et al. One year in review 2019: systemic sclerosis. Clin Exp Rheumatol. 2019;37 Suppl 119(4):3-14.
37 Heo J. DongEuiBoGam. 1st ed. Seoul: Publisher DongEuiBoGam. 2006:1023.
38 Editorial board of Traditional Korean Dermatology&Surgery. Text of Traditional Korean Dermatology & Surgery. 1st ed. Seoul: Seon Woo. 2007:484.
39 Kim DH, Jung YS, Yoon M, Yoon Y, Shin SS. Analysis for Compatibility of Gyejibongnyeong-hwan and Its Biological Activities. Herbal Formula Science. 2016;24(4):353-65.   DOI
40 Editorial board of Herbal Formula Science in Korean Medicine. Herbal Formula Science in Korean Medicine. 1st ed. Seoul: Koonja. 2020:998.
41 Editorial board of Herbalogy. Herbalogy. 1st ed. Seoul: Younglimsa. 2004:210, 461, 580.
42 Liu H, Wei W, Sun WY, Li X. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells. J Ethnopharmacol. 2009;122(3):502-8.   DOI
43 Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int. 2007;51(6-7):361-9.   DOI
44 Peng CH, Huang CN, Hsu SP, Wang CJ. Penta-acetyl geniposide-induced apoptosis involving transcription of NGF/p75 via MAPK-mediated AP-1 activation in C6 glioma cells. Toxicology. 2007;238(2-3):130-9.   DOI